- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Temozolomide for the treatment of malignant glioma
Drug guidance
Temozolomide for the treatment of malignant glioma
Condition
Cancer
Neurology
16 October 2017
Published on 16 Oct 2017
Last Updated on 16 Oct 2017
Guidance Recommendation
The Ministry of Health's Drug Advisory Committee has recommended:
Temozolomide 20mg and 100mg capsules in line with their registered indications for the treatment of:
Newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment, and
Malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Subsidy status
Generic temozolomide 20mg and 100mg capsules are recommended for inclusion on the Standard Drug List (SDL).